Michael M Goldberg
CIK 905011 · President & CEO · last filed 2017-05-16
Michael M Goldberg is a President & CEO who has filed 27 SEC Form 4 insider transactions across 4 companies since 2007. The most recent filing shows the insider was granted $48.8K of NAVB on May 16, 2017. Across all open-market trades the lifetime net is +$107.7K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $1.4M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
NAVB price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
152 WEST 57TH STREET, 4TH FLOOR
NEW YORK, NY 10019
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| NAVIDEA BIOPHARMACEUTICALS, INC. (NAVB) Delisted | President & CEO | 296,051 | $0.00 | $30 | $107.7K | 12 | 2017-05-16 |
| Echo Therapeutics, Inc. (ECTE) Delisted | Director | 14,500 | — | — | $0 | 4 | 2016-03-22 |
| Savara Inc (ANX) Delisted | Director | — | — | — | $0 | 4 | 2010-07-01 |
| EMIS | Director | 135,123 | $10.38 | $1.40M | $0 | 2 | 2007-08-31 |
Recent Filings
27 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-05-16 | NAVIDEA BIOPHARMACEUTICALS, INC. (NAVB) Delisted | Grant (A) | +106,021 | $48.8K | EDGAR |
| 2017-03-23 | — | Grant (A) | +25,000 | $0 | |
| 2017-01-19 | NAVIDEA BIOPHARMACEUTICALS, INC. (NAVB) Delisted | Exer (X) | +5,411,850 | $54.1K | EDGAR |
| 2016-10-19 | NAVIDEA BIOPHARMACEUTICALS, INC. (NAVB) Delisted | Other (J) | — | $0 | EDGAR |
| 2016-07-07 | NAVIDEA BIOPHARMACEUTICALS, INC. (NAVB) Delisted | Grant (A) | +43,580 | $21.8K | EDGAR |
| 2016-04-29 | NAVIDEA BIOPHARMACEUTICALS, INC. (NAVB) Delisted | Grant (A) | +28,000 | $0 | EDGAR |
| 2016-03-22 | Echo Therapeutics, Inc. (ECTE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-03-03 | Echo Therapeutics, Inc. (ECTE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-10-20 | NAVIDEA BIOPHARMACEUTICALS, INC. (NAVB) Delisted | Grant (A) | +13,247 | $29.9K | EDGAR |
| 2015-03-30 | NAVIDEA BIOPHARMACEUTICALS, INC. (NAVB) Delisted | Grant (A) | +22,000 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.